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Background. Observational data suggest ceftaroline may be effective for methicillin-resistant Staphylococcus aureus (MRSA)
bloodstream infection (BSI), but comparative data with standard of care are limited. This analysis compares the outcomes of MRSA
BSI treated with ceftaroline or daptomycin.
Methods. Multicenter, retrospective, observational cohort study of adult patients with MRSA BSI from 2010 to 2017. Patients
treated with ≥72 hours of ceftaroline or daptomycin were included. Those clearing BSI before study drug and those with a pneumonia source were excluded. The primary outcome was composite treatment failure, defined as 30-day mortality, BSI duration ≥7
days on study drug, and 60-day MRSA BSI recurrence. Inverse probability of treatment weighted risk difference in composite failure
between daptomycin and ceftaroline groups was computed and 15% noninferiority margin applied.
Results. Two hundred seventy patients were included; 83 ceftaroline and 187 daptomycin. Ceftaroline was noninferior to
daptomycin with respect to composite failure (39% daptomycin, 32.5% ceftaroline; weighted risk difference, 7.0% [95% confidence
interval, –5.0% to 19.0%]). No differences between treatment groups was observed for 30-day mortality or other secondary efficacy
outcomes. Creatine phosphokinase elevation was significantly more common among daptomycin patients (5.3% vs 0%, P = .034).
Rash was significantly more common among ceftaroline patients (10.8 vs 1.1%, P = .001).
Conclusions. No difference in treatment failure or mortality was observed between MRSA BSI treated with ceftaroline or
daptomycin. These data support future study of ceftaroline as a primary MRSA BSI treatment and current use of ceftaroline when an
alternative to vancomycin and daptomycin is required.
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Methicillin-resistant Staphylococcus aureus (MRSA) is a serious public health threat resulting in thousands of infections
and deaths annually [1]. A major contributor to the associated
morbidity and mortality is MRSA bloodstream infection (BSI)
[2, 3]. Vancomycin has been the treatment of choice for MRSA
BSI for decades, but treatment failure rates are in excess of 30%
[4–6]. This, along with emergence of reduced-vancomycinsusceptibility phenotypes and vancomycin-associated adverse
drug reactions, necessitates alternative treatment options.
Despite availability of newer alternative anti-MRSA antibiotics, none have been shown to be conclusively more effective
than vancomycin [6–11]. Daptomycin is currently the vancomycin alternative with the most available clinical evidence
and the only US Food and Drug Administration (FDA) alternative for S aureus BSI and right-sided infective endocarditis
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METHODS
Study Design and Population

This was a multicenter, retrospective, observational cohort study
of adult patients with MRSA BSI from 2010 to 2017 in 10 acutecare hospitals: Detroit Medical Center and Henry Ford Hospital
in Detroit, Michigan; University of Florida Health, Shands
Hospital in Gainesville, Florida; Lee Memorial Hospital in Fort
Myers, Florida; University of Tennessee Medical Center in
Knoxville, Tennessee; University of Maryland Medical Center in
Baltimore, Maryland; San Diego Veterans Affairs Medical Center
in San Diego, California; Huntsville Hospital in Huntsville,
Alabama; HonorHealth John C. Lincoln Medical Center in
Phoenix, Arizona; and Our Lady of the Lake Regional Medical
Center in Baton Rouge, Louisiana. Patients aged ≥18 years with
≥1 positive blood culture for MRSA who received ≥72 hours of
ceftaroline or daptomycin for MRSA BSI treatment were eligible
for inclusion [21]. Patients who received ≥96 hours of MRSA
BSI therapy prior to first dose of study therapy, cleared BSI prior
to first dose of study therapy, had a suspected pneumonia BSI
source, or had a polymicrobial BSI were excluded. Patients receiving ≥24 hours of concomitant MRSA-active therapy during
the initial 96 hours of study drug were also excluded.
Patient Consent Statement

This study was approved by the institutional review board at
each study site and at Wayne State University (WSU). Waiver of
patient informed consent was granted.
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Patient Data Elements and Collection

Eligible patients were identified for inclusion by screening a
list of patients who received either ceftaroline or daptomycin
during the study period. Patient data were extracted from the
medical record by trained reviewers using a structured data
collection form within the REDCap (Research Electronic Data
Capture, Vanderbilt University) data capture tool hosted at
WSU [22]. Data elements included demographics, past medical history, comorbid conditions, antibiotic therapy and associated laboratory parameters, infectious diseases consult, and
pursuit of source control. The degree of patient comorbidity
was quantified using the Charlson Comorbidity Index [23].
Severity of illness was quantified using the Acute Physiology
and Chronic Health Evaluation II (APACHE II) score using
the worst physiological parameters within 24 hours of index
MRSA blood culture [24]. Source of MRSA BSI and/or metastatic foci of infection was based on treating physicians’ notes
and available clinical/diagnostic data. Microbiologic data
including antibiotic susceptibilities by Microscan (Siemens
Healthcare Diagnostics), Vitek-2 (bioMérieux), Phoenix
(BD), and/or Etest (bioMérieux) were collected from the medical record.
Outcomes

The primary outcome was composite treatment failure, defined
as any of the following: mortality within 30 days of first dose
of study therapy, BSI duration ≥7 days after first dose of study
therapy [12], or MRSA BSI recurrence within 60 days of the end
of MRSA BSI therapy. Secondary efficacy outcomes included
each single component of composite failure, 60-day readmission related to MRSA bacteremia defined as presence of positive blood cultures on readmission, BSI duration post–study
drug initiation, and length of stay post–study drug initiation.
Multiple safety outcomes of interest were included. Creatine
phosphokinase (CPK) elevation was defined as an increase to
>600 U/L or >1000 U/L if baseline CPK was >200 U/L [25].
Neutropenia was defined as a decrease in absolute neutrophil
count (ANC) to <1500 cells/mm3 or ≥50% decline from initiation of study medication if baseline ANC <1500 cells/mm3 [26].
Clostridioides difficile infection was defined as signs/symptoms
along with positive laboratory test at least 48 hours after initiation of study therapy. Any adverse event apart from those defined above (eg, nausea, vomiting, rash) that was attributed to
a study medication in the medical record by the treating physician was also recorded.
Data Analysis

The primary analysis focused on comparing composite treatment failure between patients receiving ceftaroline and
daptomycin. We hypothesized that composite failure would
be approximately equal between ceftaroline and daptomycin
based on previously published data. Thus, the primary analysis
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[12, 13]. However, the use of daptomycin for MRSA BSI is not
without limitation. Similar to vancomycin, daptomycin failure
is common and nonsusceptibility, although rare, has emerged
[14–17]. Data suggest that as S aureus becomes less susceptible to vancomycin, susceptibility to daptomycin may also decrease [18]. Interactions with pulmonary surfactant also render
daptomycin ineffective for BSI secondary to pneumonia source,
which is an important subpopulation of MRSA BSI [19].
Ceftaroline fosamil, the prodrug of ceftaroline, is an
advanced-generation cephalosporin with potent bactericidal
gram-positive activity including against MRSA and many
strains exhibiting reduced vancomycin susceptibility and
daptomycin nonsusceptibility [20]. Observational data suggest that ceftaroline may be effective for MRSA BSI, but data
comparing ceftaroline to standard of care are limited, and
ceftaroline is not FDA approved for this indication. Without
additional comparative data, clinicians may be hesitant to use
ceftaroline, even when alternatives to vancomycin are required.
Considering that vancomycin and/or daptomycin alternatives
are frequently necessary for MRSA BSI management, these data
are urgently needed. Because daptomycin is the primary vancomycin alternative, the objective of this study was to compare
clinical outcomes between patients treated with ceftaroline or
daptomycin for MRSA BSI.

RESULTS

A total of 270 patients were included. A full description of demographics, clinical characteristics, and outcomes of the cohort
is available in Supplementary Table 1. The cohort was predominantly African American (52.6%) and White (42.2%), majority male (64.8%), and had a median age of 58 (interquartile
range [IQR], 46–66.5) years. Common comorbidities were diabetes (38.5%), moderate/severe renal disease (40.0%), chronic
hemodialysis (20.0%), heart failure (24.1%), injection drug
use (24.1%), and liver disease (21.1%). The median Charlson
Comorbidity Index and APACHE II scores were 2.5 (IQR, 1.0–
5.0) and 14.0 (IQR, 9.0–19.0), respectively. The most common
MRSA BSI sources/foci were endovascular (34.8%), bone/joint
(31.1%), skin and soft tissue (20.4%), and intravenous catheter
(19.3%). Composite failure occurred in 100 (37%) patients: 32
(11.9%) with 30-day mortality, 50 (18.5%) with BSI duration ≥7
days on study therapy, and 38 with (14.1%) 60-day MRSA BSI
recurrence.
Eighty-three patients (30.7%) were in the ceftaroline group
while 187 (69.3%) were in the daptomycin group. The majority of patients in both the ceftaroline group (71.1%) and
daptomycin group (66.3%) initially received vancomycin
therapy prior to study therapy. The most common ceftaroline
dose was 600 mg (68.7%) and the most common dosing frequencies were every 12 hours (56.6%) and every 8 hours
(42.2%). The median daptomycin dose was 600 mg (IQR, 500–
700 mg), which equates to 7.7 (IQR, 6.1–9.3) mg/kg of total
body weight and 8.5 (IQR, 6.9–10.1) mg/kg of adjusted body
weight. Using total body weight for nonobese (body mass index
[BMI] <30 kg/m2) daptomycin patients, and adjusted body
weight for obese daptomycin patients (BMI ≥30 kg/m2), only
5 (2.7%) daptomycin patients had a dose <6 mg/kg, whereas 63
(33.7%) had a dose ≥10 mg/kg. The median duration of inpatient ceftaroline and daptomycin was 10 (IQR, 5–18) days and 9
(IQR, 6–15) days, respectively.
A complete bivariate comparison of patient characteristics
between the ceftaroline and daptomycin groups in the unadjusted cohort is displayed in Table 1. While select comorbidities
were significantly different between groups, the distribution of
Charlson Comorbidity Index was similar. A similar proportion of patients had acute kidney injury at index culture and
the distribution of APACHE II scores was similar between
groups. A similar proportion of patients in each group had an
endovascular BSI source/foci. However, skin/soft tissue source/
foci was significantly more common in the ceftaroline group
whereas intravenous catheter source/foci was significantly
more common in the daptomycin group. Median time from
index blood culture to study drug was similar in both groups
(42 [IQR, 20–71] hours for ceftaroline vs 44 [IQR, 21–71]
hours for daptomycin). However, daptomycin was significantly
more likely to be the first MRSA BSI treatment compared to
ceftaroline.
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was designed to test noninferiority of ceftaroline compared to
daptomycin. Assuming a 25% incidence of composite treatment
failure in both treatment groups, a noninferiority margin of
15%, and a 2:1 daptomycin to ceftaroline allocation ratio, a minimum of 156 and 78 patients was required in the daptomycin
and ceftaroline groups, respectively, to yield a statistical power
of 80% and an α = 2.5% [13, 27, 28]. Actual and weighted risk
differences with 95% confidence intervals (CIs) were computed
for composite failure between the daptomycin and ceftaroline
groups (ie, daptomycin minus ceftaroline). Ceftaroline was considered noninferior if the lower bound of the 95% CI for this
risk difference did not cross –15%.
Weighted risk differences were based on inverse probability
of treatment weighting (IPTW). This was employed to address
the high likelihood of confounding and treatment selection
bias introduced by the fact that treatment assignment was not
random. Logistic regression was used to estimate each patient’s
probability of receiving ceftaroline (ie, a propensity score).
The model included a priori–identified covariates known to
be associated with mortality and/or microbiologic failure in
patients with MRSA BSI including age, BSI source/foci of infection, Charlson Comorbidity Index, APACHE II score, infectious diseases consult, and source control [5, 29–34]. Stabilized
weights for each subject were generated from the inverse of the
propensity score. A pseudo-cohort was then generated using
these stabilized weights, and the standardized difference between treatment groups of each a priori–identified covariate
of importance was examined to ensure balance was achieved.
A threshold of >25% standardized difference was used to assess the need for a respecified propensity score model, and a
threshold of >10% was used to assess the need for further adjustment of a covariate in outcome analysis [35–37].
Secondary analyses were also conducted to compare secondary efficacy and safety outcomes between treatment groups
and using actual and weighted risk differences in a manner
consistent with the primary analysis. Secondary analyses
evaluating composite failure between treatment groups in both
a priori–specified and post hoc subgroups of interest were also
conducted. These subgroups included infective endocarditis
BSI source/foci, skin and soft tissue BSI source/foci, bone/joint
BSI source/foci, patients with chronic kidney disease stage 3
or greater, patients on intermittent hemodialysis, and patients
with acute kidney injury (Acute Kidney Injury Network stages
1–3).
When comparing patient characteristics and outcomes between those receiving ceftaroline or daptomycin, the χ2 or
Fisher exact test was used for categorical variables and the
Mann-Whitney U test was used for continuous and numeric
ordinal variables. All statistical tests were 2-sided; P values ≤
.05 were considered statistically significant. Analyses were performed using SAS software version 9.4 (SAS Institute, Cary,
North Carolina).

Table 1.

Bivariate Comparisons of Demographic and Clinical Characteristics Between Patients Receiving Daptomycin or Ceftaroline

Covariate

Daptomycin (n = 187)

Ceftaroline (n = 83)

P Value

Demographics

 Obesityd
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58 (48–68)
117 (62.6)

56 (40–63)
58 (69.9)

.248
.246

120 (64.3)
57 (30.5)
3 (1.6)
1 (0.5)
6 (5.5)

22 (26.5)
57 (35.0)
1 (1.2)
1 (1.2)
2 (2.4)

<.001
<.001
1.000
.521
1.000

122 (65.2)
24 (12.8)
23 (12.3)
0
15 (8.0)
3 (1.6)
0
0
0
0

12 (14.5)
11 (13.3)
7 (8.4)
17 (20.5)
1 (1.2)
10 (12.0)
11 (13.3)
9 (10.8)
3 (3.6)
2 (2.4)

<.001
.925
.351
<.001
.027
.001
<.001
<.001
.028
.094

17 (9.1)
47 (25.1)
37 (19.8)
25 (13.4)
8 (4.3)
42 (22.5)
29 (15.5)
19 (10.2)
25 (13.4)
0
34 (18.2)
28 (15.0)
6 (3.2)
74 (39.6)
17 (9.1)
57 (30.5)
9 (4.8)
82 (43.9)
44 (23.5)
6 (3.2)
1 (0.5)
1 (0.5)
2 (1.1)
7 (3.7)
0
3 (1–5)
37 (19.8)
76 (40.6)
51 (27.3)
33 (17.6)
22 (11.8)
0

11 (13.3)
18 (21.7)
8 (9.6)
10 (12.0)
3 (3.6)
15 (18.1)
12 (14.5)
3 (3.6)
4 (4.8)
0
23 (27.7)
19 (22.9)
4 (4.8)
30 (36.1)
10 (12.0)
20 (24.1)
0
26 (31.3)
10 (12.0)
2 (2.4)
3 (3.6)
0
2 (2.4)
2 (2.4)
2 (2.4)
2 (1–5)
28 (33.7)
25 (30.1)
20 (24.1)
14 (16.9)
5 (6.0)
3 (3.6)

.301
.541
.039
.766
.799
.415
.824
.070
.036
.077
.113
.502
.593
.455
.061
.053
.030
1.000
.088
1.000
.589
.726
.094
.275
.013
.099
.584
.876
.189
.028
.471

137 (73.7)
24 (12.9)
25 (13.4)
79.8 (68.0–96.0)
26.6 (23.4–32.6)
60 (32.1)

66 (62.6)
10 (12.0)
7 (9.9)
83.6 (72.6–99.5)
27.2 (23.7–32.4)
29 (34.9)

.235
.614
.645
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 Age, y, median (IQR)
 Male sex
 Race/ethnicity
  African American
  White
  Asian
  
Hispanic
  
Other/unknown
Study site
 Detroit Medical Center
 UF Health–Shands Hospital
 Henry Ford Hospital
 University of Tennessee Medical Center
 Lee Memorial Hospital
 University of Maryland Medical Center
 VA San Diego Healthcare System
 Huntsville Hospital
 HonorHealth John C. Lincoln Medical Center
 Our Lady of the Lake Medical Center
Comorbidities and past medical history
 Myocardial infarction
 Heart failure
 Peripheral vascular disease
 Cerebrovascular disease
 Dementia
 Chronic pulmonary disease
  
COPD
  Asthma
 Connective tissue disease
 Peptic ulcer disease
 Liver disease
  
Milda
  
Moderate/severeb
 Diabetes
  Without end-organ damage
  With end-organ damage
 Hemiplegia
 Moderate/severe renal diseasec
 Chronic hemodialysis
 Solid tumor without metastasis
 Leukemia
 Lymphoma
 Metastatic solid tumor
 HIV
 AIDS
 Charlson Comorbidity Index, median (IQR)
 Intravenous drug use
 Prior hospitalization (90 d)
 Prior MRSA infection (1 y)
 Prior IV vancomycin (90 d)
 Prior daptomycin (90 d)
 Prior ceftaroline (90 d)
Clinical data
 Admitted from:
  
Home
  Transferred from another hospital
  
Nursing facility
 Weight, kg, median (IQR)
 BMI, kg/m2, median (IQR)

Table 1.

Continued

Covariate

Daptomycin (n = 187)

Ceftaroline (n = 83)

 Creatinine clearancee,f, mL/min, median (IQR)

61.7 (35.7–95.4)

62.6 (35.8–104.9)

  
>50 mL/min

89 (47.6)

47 (56.6)

  
30.01–50 mL/min

30 (16.0)

14 (16.9)

P Value
.861
.350

  
15–30 mL/min

21 (11.2)

9 (10.8)

  <15 mL/min or ESRD

47 (25.1)

13 (15.7)

 Acute kidney injuryf

61 (32.6)

29 (34.9)

 APACHE II scoref, median (IQR)

14 (9–20)

14 (9–19)

.527

3 (1.6)

1 (1.2)

1.000

 Endovascular

65 (34.8)

29 (34.9)

.977

  
Infective endocarditis

55 (29.4)

27 (32.5)

.607

  
Other endovascular

11 (5.9)

2 (2.4)

.356

4 (2.1)

2 (2.4)

1.000

 Neutropeniaf

.709

Infection data

 Lower respiratory tract

0

0

 Bone/joint

56 (29.9)

28 (33.7)

.535

 Invasive prosthetic device

20 (10.7)

4 (4.8)

.117

 Skin/soft tissue

32 (17.1)

23 (27.7)

.046

 Deep tissue abscess

13 (7.0)

9 (10.8)

.281

 Intravenous catheter

42 (22.5)

10 (12.0)

.045

 Urinary

5 (2.7)

1 (1.2)

.670

 Unknown

8 (4.3)

5 (6.0)

.546

173 (93.0)

82 (98.8)

.071

97 (52.4)

36 (43.9)

.198

62 (33.2)

16 (19.3)

124 (66.3)

64 (77.1)

1 (0.5)

3 (3.6)

122 (65.2)

59 (71.1)

Treatment data
 Infectious diseases consult
 Source control pursued
 Study drug line of therapyg
  
First-line
  
Second-line
  Third-line

.014

 Preceding MRSA BSI therapy
  Vancomycin
  
Daptomycin

0

6 (7.2)

  
Ceftaroline

1 (0.5)

0

  
Linezolid
 Time to study drug, h, median (IQR)
 Ceftaroline dose (n = 83)

3 (1.6)

6 (7.2)

44 (21–71)

42 (20–71)

  
600 mg

57 (68.7)
12 (14.5)

  
300 mg

11 (13.3)

  
200 mg

.026
.964

3 (3.6)
…

  Every 8 h

35 (42.2)

  Every 12 h

47 (56.6)

  Every 24 h
 Daptomycin dose, mg, median (IQR)

.001
1.000

…

  
400 mg

 Ceftaroline dose interval (n = 83)

.346

1 (1.2)
600 (500–770)

…

 Daptomycin dose, mg/kg (actual body weight), median (IQR)

7.7 (6.1–9.3)

…

 Daptomycin dose, mg/kg (adjusted body weight), median (IQR)

8.5 (6.9–10.1)

…

120 (64.2)

…

 Daptomycin dose interval
  Every 24 h
  
Every 48 h/posthemodialysis
 Inpatient study drug duration, d, median (IQR)

67 (35.8)

…

9 (6–15)

10 (5–18)

.545

Data are presented as No. (%) unless otherwise indicated.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; BMI, body mass index; BSI, bloodstream infection; COPD chronic obstructive pulmonary disease; ESRD, end-stage
renal disease; HIV, human immunodeficiency virus; IQR, interquartile range; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; UF, University of Florida; VA, Veterans Affairs.
a

Mild liver disease defined as chronic hepatitis without cirrhosis.

b

Severe liver disease defined as portal hypertension or cirrhosis.

c

Moderate/severe renal disease defined as chronic kidney disease stage 3 or greater or receiving chronic dialysis.

d

Defined as BMI ≥30 kg/m2.

e

Calculated using Cockcroft-Gault formula using actual body weight for BMI <30 kg/m2 and adjusted body weight for BMI ≥30 kg/m2.

f

At time of index MRSA blood culture.

g

Reasons for switch to daptomycin or ceftaroline, when documented, included elevated vancomycin minimum inhibitory concentration, concern for failure or previous therapy, concern for
adverse reaction on previous therapy, and perceived improved target site penetration.
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 Intra-abdominal
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Decrease in absolute neutrophil count (ANC) to <1500 cells/mm3 or ≥50% decline from initiation of study medication if baseline ANC <1500 cells/mm3.

Clostridioides difficile infection defined as signs/symptoms along with positive laboratory test at least 48 hours after initiation of study drug.

e

f

Increase to >600 U/L or >1000 U/L if baseline CPK >200 U/L.
d

P value for χ2 test of weighted risk differences.

Includes CPK elevation, neutropenia, rash, Clostridioides difficile infection (data presented in table), and additional adverse reactions occurring while on study drug or attributed to study drug by treating clinicians, such as acute kidney injury, thrombocytopenia, fever, hypotension and bradycardia, and eosinophilic pneumonia.

P value for χ2 or Fisher exact test of actual risk differences.

b

a

Abbreviations: BSI, bloodstream infection; CI, confidence interval; CPK, creatine phosphokinase; MRSA, methicillin-resistant Staphylococcus aureus.

Data are presented as No. (%) unless otherwise indicated.

2 (1.1)
Clostridioides difficile infectionf

c

.076
–3.3 (–7.8 to 1.2)
.074
–3.8 (–8.6 to 1.1)

…
0
0
Neutropeniae

4 (4.8)

.001
…

.034

–8.0 (–14.3 to –1.8)
2 (1.1)
Rash

9 (10.8)

–9.8 (–16.6 to –2.9)

.001

.164

5.0 (1.9 to 8.1)
10 (5.4)
CPK elevationd

0

5.4 (2.1–8.6)

.034

.718

–6.3 (–15.7 to 3.1)
24 (12.8)
Adverse drug reactionc

17 (20.5)

–7.7 (–17.6 to 2.3)

.106

.085

1.3 (–5.8 to 8.4)
17 (9.1)
60-d MRSA BSI-related readmission

6 (7.2)

1.9 (–5.1 to 8.8)

.613

.273

7.8 (–.002 to 15.9)
31 (16.6)
60-d MRSA BSI recurrence

7 (8.4)

8.1 (.001–16.2)

.076

.215

5.4 (–3.8 to 14.5)
36 (19.3)
BSI duration ≥7 d

14 (16.9)

2.4 (–7.5 to 12.2)

.642

.264
7.0 (–5.0 to 19.0)

–5.2 (–13.8 to 3.5)
.377

.307
6.5 (–5.8 to 18.8)

–3.8 (–12.5 to 5.0)
12 (14.5)
20 (10.7)
30-d mortality

27 (32.5)
73 (39.0)
Composite failure

P Valueb
Weighted Risk Difference (95% CI)
P Valuea
Risk Difference (95% CI)
Ceftaroline (n = 83)
Daptomycin (n = 187)
Outcome

Actual and Inverse Probability of Treatment Weighted Risk Differences Between Daptomycin and Ceftaroline for the Primary and Secondary Outcomes

This study sought to compare the effectiveness and safety of
ceftaroline and daptomycin for the treatment of MRSA BSI.
Patients receiving ceftaroline and daptomycin had similar treatment outcomes in both unadjusted and IPTW-adjusted analysis designed to mitigate the influence of treatment selection
bias and confounding. This was also true in the prespecified
subgroup analysis, most notably patients with an infective endocarditis source/foci and those with moderate/severe renal
impairment. The only notable differences in outcome observed
between the 2 treatment groups was with respect to safety outcomes. Not surprisingly, patients treated with ceftaroline were
more likely to develop a rash whereas patients treated with
daptomycin were more likely to experience a CPK elevation.

Table 2.

DISCUSSION
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Table 2 shows the actual and weighted risk differences between the daptomycin and ceftaroline groups for treatment
outcomes. No significant difference in composite treatment
failure was observed between daptomycin and ceftaroline
patients (39% daptomycin, 32.5% ceftaroline; weighted
risk difference, 7.0% [95% CI, –5.0% to 19.0%]). This met
the definition of noninferiority of ceftaroline compared to
daptomycin for composite treatment failure. No statistically
significant difference in any of the secondary efficacy outcomes was observed between daptomycin and ceftaroline patients, including 30-day mortality. No significant difference
in BSI duration post–study drug initiation was observed between treatment groups (daptomycin, 3 [IQR, 2–5] days vs
ceftaroline, 4 [IQR, 2–6] days; P = .134). Similarly, length
of stay post–study drug initiation was not different between
groups (daptomycin, 11 [IQR, 7–18] days vs ceftaroline,
13 [IQR, 7–24] days; P = .095). With respect to safety outcomes, creatine phosphokinase elevation was significantly
more common among daptomycin patients whereas rash
was significantly more common among ceftaroline patients
(Table 2). No significant difference was noted in any other
safety outcome. Clostridioides difficile infection occurred
numerically more frequently in the ceftaroline group. There
were no cases of study drug–associated neutropenia in either
group. There were 2 cases of eosinophilic pneumonia in the
daptomycin group.
The results of the a priori secondary subgroup analyses are
displayed in Table 3. The results were consistent with primary
analyses. No statistically significant association was observed
between treatment group and composite failure in any of the
subgroups of interest. The results of the post hoc subgroup analyses evaluating composite failure by study drug line of therapy
are displayed in Supplementary Table 2. No statistically significant association was observed between treatment group and
composite failure when study therapy was used as first-line or
second-line therapy.
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P value for χ2 test of weighted risk differences.

P value for χ2 or Fisher exact test of actual risk differences.

b

a

Abbreviation: CI, confidence interval.

29/61 (47.5)
Acute kidney injury (n = 90)

Data are presented as no./No. (%) unless otherwise indicated.

.870

.260
13.2 (–9.1 to 35.5)
.243
13.1 (–8.3 to 34.4)

.951

18/44 (40.9)
Chronic hemodialysis (n = 54)

10/29 (34.5)

2.5 (–27.1 to 32.1)
.723
10.9 (–21 to 42.8)

.095

37/82 (45.1)
Moderate/severe renal disease (n = 108)

3/10 (30)

–0.6 (–21.3 to 20)
.801
2.8 (–19 to 24.7)

.840

25/56 (44.6)

11/26 (42.3)

19.8 (–1.9 to 41.4)
.155
16.1 (–5.1 to 37.3)

.299

Bone/joint source/foci (n = 84)

8/28 (28.6)

–2.8 (–30 to 24.5)

12.2 (–10.2 to 34.7)
.295

.759
3.9 (–21.1 to 28.9)

12.1 (–10.0 to 34.2)

11/32 (34.4)
Skin/soft tissue source/foci (n = 55)

9/27 (33.3)
25/55 (45.5)
Infective endocarditis source/foci (n = 82)

7/23 (30.4)

P Valueb
Weighted Risk Difference (95% CI)
P Valuea
Risk Difference (95% CI)
Ceftaroline
Daptomycin
Subgroup

Actual and Inverse Probability of Treatment Weighted Risk Differences Between Daptomycin and Ceftaroline for the Composite Treatment Failure in A Priori–Specified Subgroups of Interest
Table 3.

Downloaded from https://academic.oup.com/ofid/article/9/3/ofab606/6481735 by Henry Ford Hospital user on 02 May 2022

The results of this study contribute to a growing body of
clinical evidence suggesting that ceftaroline may be a viable
treatment option for MRSA BSI. Numerous noncomparative
observational studies have demonstrated the potential utility
of ceftaroline for MRSA BSI. These data are the first clinical
data comparing ceftaroline to daptomycin, a standard-of-care
therapy for MRSA BSI. Although observational in nature, and
thus unable to firmly establish ceftaroline as noninferior to
daptomycin, these data do represent an increase in the level
and quality of the evidence to support the use of ceftaroline for
MRSA BSI. Ceftaroline should be a priority for inclusion into
future randomized clinical trials evaluating novel treatments for
MRSA BSI in order to fully delineate its place in therapy.
There are a number of considerations to bear in mind when
interpreting these findings. First and foremost, although we
conducted noninferiority testing on the primary outcome of
composite treatment failure, the observational nature of this
study precludes the ability to conclude that ceftaroline is truly
noninferior to daptomycin for MRSA BSI. That would require
one or more robustly designed randomized controlled trials.
The noninferiority testing was conducted due to the fact that we
wanted to power the study under the hypothesis that there would
be no difference in failure between ceftaroline and daptomycin.
A noninferiority margin of 15% was selected a priori due to
the anticipated difficulty in obtaining a large enough sample of
ceftaroline monotherapy–treated patients to use a stricter margin
and the fact that a less-strict noninferiority margin of 20% was
used to conclude daptomycin was noninferior to vancomycin for
MRSA BSI [6]. Readers should note that a noninferiority margin
of 10% would have been ideal considering that a 10% difference
in treatment failure is clinically meaningful. Although the primary analysis suggests that it is statistically unlikely the incidence of failure is more than 5% greater in the ceftaroline group,
noninferiority at any threshold <15% cannot be concluded because the study was not powered to do so.
It is also important to note that the study therapy was not the
initial MRSA BSI therapy for the majority of the patients in this
study, particularly those in the ceftaroline group. It is unclear
whether the results would be similar if more patients had been
given ceftaroline or daptomycin as first-line therapy. It is encouraging that the majority of patients in both treatment groups
received study therapy within 48 hours of index culture. This is
similar to currently published randomized clinical trials where
the transition from standard of care to experimental therapy
often takes up to 48 hours [6]. However, this similarity with
published clinical trials does not nullify the potential impact
that studying sequential therapy could have. Data suggest that
the initial 24–48 hours of MRSA BSI therapy is most strongly
associated with outcome [34, 38]. Ideally, the comparison of 2
MRSA BSI treatments would occur during this early timeframe
to best capture treatment effect and minimize the potential bias
and confounding imparted by prior treatment.

Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
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the authors, so questions or comments should be addressed to the corresponding author.
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